Citadel Advisors’s Citius Pharmaceuticals CTXR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Hold |
0
| – | – | – | 6005 |
|
|
2025
Q1 | – | Sell |
-1
| Closed | -$4 | – | 6093 |
|
|
2024
Q4 | $4 | Buy |
+1
| New | +$4 | ﹤0.01% | 5903 |
|
|
2024
Q3 | – | Sell |
-7,425
| Closed | -$108K | – | 5919 |
|
|
2024
Q2 | $108K | Buy |
+7,425
| New | +$108K | ﹤0.01% | 4923 |
|
|
2024
Q1 | – | Hold |
0
| – | – | – | 6203 |
|
|
2023
Q4 | – | Sell |
-194
| Closed | -$3.32K | – | 5991 |
|
|
2023
Q3 | $3.32K | Buy |
194
+163
| +526% | +$2.79K | ﹤0.01% | 5565 |
|
|
2023
Q2 | $944 | Sell |
31
-3,461
| -99% | -$105K | ﹤0.01% | 5627 |
|
|
2023
Q1 | $102K | Sell |
3,492
-12,195
| -78% | -$357K | ﹤0.01% | 4901 |
|
|
2022
Q4 | $310K | Buy |
15,687
+11,432
| +269% | +$226K | ﹤0.01% | 4298 |
|
|
2022
Q3 | $129K | Sell |
4,255
-5,180
| -55% | -$157K | ﹤0.01% | 5023 |
|
|
2022
Q2 | $217K | Buy |
9,435
+4,954
| +111% | +$114K | ﹤0.01% | 4933 |
|
|
2022
Q1 | $200K | Sell |
4,481
-1,044
| -19% | -$46.6K | ﹤0.01% | 5318 |
|
|
2021
Q4 | $213K | Buy |
5,525
+910
| +20% | +$35.1K | ﹤0.01% | 5428 |
|
|
2021
Q3 | $234K | Sell |
4,615
-3,753
| -45% | -$190K | ﹤0.01% | 5254 |
|
|
2021
Q2 | $728K | Buy |
8,368
+7,248
| +647% | +$631K | ﹤0.01% | 4360 |
|
|
2021
Q1 | $50K | Buy |
1,120
+364
| +48% | +$16.3K | ﹤0.01% | 6097 |
|
|
2020
Q4 | $19K | Buy |
+756
| New | +$19K | ﹤0.01% | 4982 |
|
|
2020
Q3 | – | Sell |
-697
| Closed | -$20K | – | 4747 |
|
|
2020
Q2 | $20K | Buy |
697
+271
| +64% | +$7.78K | ﹤0.01% | 4486 |
|
|
2020
Q1 | $6K | Buy |
+426
| New | +$6K | ﹤0.01% | 4770 |
|
|
2019
Q2 | – | Sell |
-1,063
| Closed | -$38K | – | 4704 |
|
|
2019
Q1 | $38K | Buy |
+1,063
| New | +$38K | ﹤0.01% | 4297 |
|